{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.2","value":"15.3"},{"groupId":"OG001","spread":"13.4","value":"13.2"},{"groupId":"OG002","spread":"8","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"111"}],"units":"Participants"}],"description":"Quality of life EORTC-QLQ-CIPN20. International EORTC questionnaire to assess Chemotherapy-Induced Peripheral Neuropathy (CIPN).\n\nA total QLQ-CIPN20 score can range from 0 to 100, higher score means worse outcome. Chemotherapy-induced peripheral neuropathy (CIPN) is a common phenomenon, often resulting in serious limitations in daily functioning and compromised quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Experimental group B: 5x5Gy -\\> CAPOX -\\> Surgery","id":"OG000","title":"Experimental Group"},{"description":"Standard of care group with post-operative chemotherapy Chemoradiation -\\> surgery -\\> CAPOX","id":"OG001","title":"Standard of Care Group With Post-operative Chemotherapy"},{"description":"Standard of care group without post-operative chemotherapy Chemoradiation -\\> surgery","id":"OG002","title":"Standard of Care Group Without Post-operative Chemotherapy"}],"paramType":"MEAN","populationDescription":"574 Patients without DrTF at 3 years post surgery were eligible to receive the questionnaires 495 questionnaires were returned, 453 analyzed (completed within time lines)","reportingStatus":"POSTED","timeFrame":"3 year after surgery","title":"Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC-QLQ-CIPN20)","type":"SECONDARY","unitOfMeasure":"score on a scale"}